Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

Read more ››
By: Nasdaq / GlobenewsWire - 18 Feb 2018

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

Read more ››
By: Nasdaq / GlobenewsWire - 17 Feb 2018

AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor,... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  AbbVie Inc.

AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting

NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  AbbVie Inc.

Evolus Announces Presentation of Phase III European - Canadian Comparative Data

IRVINE, Calif., Feb. 17, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at the American Academy of Dermatology (AAD) meeting.... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  Evolus, Inc.

Cardax's ZanthoSyn® is No. 1 Seller at GNC Hawaii Stores

HONOLULU, Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that ZanthoSyn(®) (60 count), the Company's premium astaxanthin dietary supplement for inflammatory health and longevity, was the top selling product in Hawaii GNC stores for the fourth quarter of 2017, based... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  Cardax, Inc.

Cardax Inks Deal to Distribute ZanthoSyn® in China

HONOLULU, Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has signed a Purchase Agreement (the "Agreement") with Health Elite Club Limited ("HECL") of Hong Kong for distribution of ZanthoSyn(®), the Company's premium astaxanthin dietary supplement for inflammatory... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  Cardax, Inc.

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more ››
By: Nasdaq / GlobenewsWire - 17 Feb 2018

LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL:  Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN

NEW ORLEANS, Feb. 16, 2018 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Lipocine Inc. (NasdaqCM: LPCN).

Read more ››
By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  Lipocine Inc.

US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER

WILMINGTON, Del., Feb. 16, 2018 /PRNewswire/ -- AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved IMFINZI(®) (durvalumab) for the treatment of patients with unresectable Stage III non-small... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  AstraZeneca Pharmaceuticals LP

Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego

DUBLIN, Feb. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, February 16-20, 2018.

Read more ››
By: PR Newswire Association LLC. - 17 Feb 2018

How Anandia Labs Reduced the Growing Pains of Managing Purchases in the Cannabis Industry Through Procurify

VANCOUVER, British Columbia, Feb. 16, 2018 /PRNewswire/ -- Cannabis is a growing industry with millions of dollars of VC funding being pumped yearly into new ventures. Smart businesses are implementing good spend cultures by having the foresight to prepare for the hyper-growth stage that will... Read more ››

By: PR Newswire Association LLC. - 17 Feb 2018
Related companies:  Anandia Labs

Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals

Read more ››
By: Nasdaq / GlobenewsWire - 16 Feb 2018

OncBioMune Provides Update on Market Activity

Read more ››
By: Nasdaq / GlobenewsWire - 16 Feb 2018

ChromaDex Chairman Stephen Allen Will Retire from Board of Directors

Read more ››
By: Nasdaq / GlobenewsWire - 16 Feb 2018

Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

EAST HANOVER, N.J., Feb. 16, 2018 /PRNewswire/ -- Novartis announced today additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx(® )(secukinumab) reported no impact of skin disease on their quality of life through... Read more ››

By: PR Newswire Association LLC. - 16 Feb 2018
Related companies:  Genomics Institute of the Novartis Research Foundation

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

SILVER SPRING, Md., Feb. 16, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer... Read more ››

By: PR Newswire Association LLC. - 16 Feb 2018
Related companies:  U.S. Food and Drug Administration

Prevagen Races To Raise Awareness For Vitamin Angels At NASCAR Xfinity Series Race In Daytona

DAYTONA, Fla., Feb. 16, 2018 /PRNewswire/ -- Prevagen is teaming up with Vitamin Angels this weekend for the NASCAR Xfinity Series: PowerShares QQQ 300 in Daytona, Florida. The Read more ››

By: PR Newswire Association LLC. - 16 Feb 2018

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2018 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on January 24, 2018 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common... Read more ››

By: PR Newswire Association LLC. - 16 Feb 2018
Related companies:  Rigel Pharmaceuticals, Inc.

Medtronic Chairman and CEO Omar Ishrak to Speak at CEO Investor Forum 3.0

Read more ››
By: Nasdaq / GlobenewsWire - 16 Feb 2018
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑